CD16-158-VALINE CHIMERIC RECEPTOR T CELLS OVERCOME THE RESISTANCE OF KRAS-MUTATED COLORECTAL CARCINOMA CELLS TO CETUXIMAB
R. Arriga, S. Caratelli, G. Lanzilli, A. Ottaviani, C. Cenciarelli, T. Sconocchia, G. C. Spagnoli, G. Iezzi, M. Roselli, D. Lauro, G. Dotti, S. Ferrone, G. Sconocchia
This study evaluates CD16-158-VALINE chimeric receptor T cells for overcoming cetuximab resistance in KRAS-mutated colorectal cancer, finding they enhance IFNγ and TNF release and control tumor growth in mice.
bioRxiv · Mar 26, 2019Immunology